Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
radiopharmaceutical
medical radioisotope |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
2018 |
| gptkbp:ATCCode |
V10XX05
|
| gptkbp:brand |
gptkb:Lutathera
|
| gptkbp:contains |
lutetium-177
dotatate |
| gptkbp:developedBy |
gptkb:Advanced_Accelerator_Applications
|
| gptkbp:halfLife |
6.65 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lutetium Lu 177 dotatate
|
| gptkbp:indication |
unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
binds to somatostatin receptors
delivers targeted radiation to tumor cells |
| gptkbp:radioactive |
beta emission
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting fatigue bone marrow suppression renal toxicity |
| gptkbp:target |
somatostatin receptor subtype 2 (SSTR2)
|
| gptkbp:usedFor |
treatment of gastroenteropancreatic neuroendocrine tumors
|
| gptkbp:bfsParent |
gptkb:PEN-221
|
| gptkbp:bfsLayer |
7
|